Year: 2015
Type: article
Abstract: Despite aggressive multimodal treatment prognosis for malignant gliomas remains poor. The low efficiency of conventional cytostatic therapy forced to look for alternative approaches to treatment. This review deals with active immunotherapy using tumor vaccines and adoptive cell therapy. Vaccinotherapy may be carried out using tumor lysates or individual peptides, or mRNA. To improve the immunogenicity of vaccines dendritic cells and various immunoadjuvants are widely used. When using lysate vaccine in patients with newly diagnosed glioblastoma multiforme median progression-free survival is 9,5–18 months, and median overall survival is 16,25–35,9 months, significantly more than the historical control. Peptide vaccines to WT-1, survivin, mutated isocitrate dehydrogenase (IDHR132H), mutated epidermal growth factor receptor (EGFRvIII) are under investigation. Promising are the methods of vaccinotherapy against glioma stem cells antigens, cytomegalovirus antigens. The possibility of integration of immunotherapy in the existing treatment standards, as well as a combination of several immunotherapeutic strategies, has been studied extensively.
Source: Malignant tumours
Authors: K. E. Borisov, DINA SAKAEVA
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W1620504461